Acasti Pharma Inc. (ACST) SEC Filing 8-K Material Event for the period ending Thursday, August 26, 2021

SEC Filings

Acasti Pharma Inc.

CIK: 1444192 Ticker: ACST

View differences made from one to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..


Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Acasti Pharma Inc. provided additional information to their SEC Filing as exhibits

Ticker: ACST
CIK: 1444192
Form Type: 8-K Corporate News
Accession Number: 0001171843-21-006192
Submitted to the SEC: Fri Aug 27 2021 8:47:23 AM EST
Accepted by the SEC: Fri Aug 27 2021
Period: Thursday, August 26, 2021
Industry: Pharmaceutical Preparations
  1. Bylaw Change
  2. Change in Assets
  3. Event for Officers
  4. Financial Exhibit
  5. Regulated Disclosure
  6. Security Holders Change
  7. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: